Enliven Therapeutics (ELVN) Capital Expenditures Growth (1y) (2021 - 2025)
Enliven Therapeutics (ELVN) Capital Expenditures Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 143.40% |
| 10 | Enliven Therapeutics | 3.39 Bn | 2.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -104.76% |
| Jun 30, 2025 | 4,533.33% |
| Mar 31, 2025 | 0.00% |
| Sep 30, 2024 | 31.25% |
| Jun 30, 2024 | -96.59% |
| Mar 31, 2024 | -35.48% |
| Dec 31, 2023 | -86.14% |
| Sep 30, 2023 | 14.29% |
| Jun 30, 2023 | -70.96% |
| Mar 31, 2023 | -84.02% |
| Mar 31, 2022 | 1,516.67% |
| Mar 31, 2021 | -20.00% |